Abstract
Two recent studies suggested that the APOE ε4 haplotype was associated with increased α-synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB), and idiopathic REM Sleep Behavior Disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB, and iRBD. We analyzed genome-wide association study (GWAS) data from 5,229 PD patients and 5,480 controls, 2,610 DLB patients and 1,920 controls, and 1,055 iRBD patients and 3,667 controls. We used logistic regression interaction models across all 3 cohorts independently between the 1) top GWAS signals of SNCA SNPs and APOE haplotypes, 2) SNP x SNP and 3-way SNP interaction across the entire coding region plus 200kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB, and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them does not affect the risk of PD, DLB and iRBD.
Competing Interest Statement
Prabhjyot Saini: Nothing to declare Eric Yu: Nothing to declare Mehrdad A Estiar: Nothing to declare Lynne Krohn: Nothing to declare Kheireddin Mufti: Nothing to declare Uladzislau Rudakou: Nothing to declare Jennifer A Ruskey: Nothing to declare Farnaz Asayesh: Nothing to declare Sandra B Laurent: Nothing to declare Dan Spiegelman: Nothing to declare Jean Francois Trempe: Nothing to declare Timothy G Quinnell: Nothing to declare Nicholas Oscroft: Nothing to declare Isabelle Arnulf: IA was previously consultant for Idorsia pharma and UCB Pharma Jacques Y Montplaisir: Nothing to declare Jean Francois Gagnon: Jean Francois Gagnon Alex Desautels: Alex Desautels received operating grants from CHIR AASM and research grants from Eisai Takeda and Canopy Growth honoraria from serving on the scientific advisory board of Eisai Paladin Labs and UCB as well as honoraria from speaking engagements from Eisai Jazz Pharma and Paladin Labs None of the financial disclosures is relevant to the submitted work Yves Dauvilliers: has served as a consultant or on advisory boards for Avadel Pharmaceuticals Jazz Pharmaceuticals UCB Takeda Pharmaceutical Co Theranexus Harmony Biosciences Bioprojet Pharma and Idorsia Gian Luigi Gigli: Nothing to declare Mariarosaria Valente: Nothing to declare Francesco Janes: Nothing to declare Andrea Bernardini: Nothing to declare Karel Sonka: Nothing to declare David Kemlink: Nothing to declare Wolfgang Oertel: Wolfgang H Oertel has received speakers honoria on educational symposia sponsored by Abbvie the International Movement Disorders Society and Stada Pharma He acts as consultant for Lario Therapeutics and is a member of advisory boards with Intrabio and MODAG He holds stock options with Intrabio not related to this manuscript and stock options with MODAG not related to this work The institution of WHO not WHO personally received s scientific grants from the Stichting ParkinsonFonds The Netherlands The ParkinsonFonds Germany related to this manuscript and scientific grants from the German Research Foundation the Michael J Fox Foundation and the Rittal Foundation unrelated to the manuscript Annette Janzen: received grants from the ParkinsonFond Deutschland Giuseppe Plazzi: Has received consultancy fees for Bioprojet Jazz Takeda Idorsia Alkermes and Centessa Elena Antelmi: Nothing to declare Francesco Biscarini: Honorarium from BioProjet Michela Figorilli: Nothing to declare Monica Puligheddu: Nothing to declare Brit Mollenhauer: Nothing to declare Claudia Trenkwalder: Nothing to declare Friederike Sixel Doring: Nothing to declare Valerie Cochen De Cock: Nothing to declare Christelle Charley Monaca: Nothing to declare Donald Grosset: Nothing to declare Anna Heidbreder: Nothing to declare Luigi Ferini Strambi: Nothing to declare Femke Dijkstra: Nothing to declare Mineke Viaene: Nothing to declare Beatriz Abril: Nothing to declare Bradley F Boeve: Honorarium for SAB activities for the Tau Consortium funded by the Rainwater Charitable Foundation institutional research grant support for clinical trials from Alector Transposon Cognition Therapeutics EIP Pharma grant support from NIH Lewy Body Dementia Association American Brain Foundation Mayo Clinic Dorothy and Harry T Mangurian Jr Lewy Body Dementia Program the Little Family Foundation the Ted Turner and Family Foundation Ronald B Postuma: RBP reports grants and personal fees from Fonds de la Recherche en Sante grants from Canadian Institute of Health Research The Michael J Fox Foundation MJFF the Webster Foundation Roche and the National Institute of Health and personal fees from Takeda Biogen AbbVie Curasen Lilly Novartis Eisai Paladin Merck Vaxxinity Korro Bristol Myers Squibb and the International Parkinson and Movement Disorders Society outside the submitted work Guy A Rouleau: Nothing to declare Abubaker Ibrahim: Nothing to declare Ambra Stefani: Nothing to declare Birgit Hogl: Nothing to declare Michele TM Hu: Nothing to declare Sonja W Scholz: SWS serves on the scientific advisory board of the Lewy Body Dementia Association Mission MSA and G Can SWS receives research support from Cerevel Therapeutics Ziv Gan Or received consultancy fees from Lysosomal Therapeutics Inc LTI Idorsia Prevail Therapeutics Ono Therapeutics Denali Handl Therapeutics Neuron23 Bial Biotech Bial UCB Capsida Vanqua bio Congruence Therapeutics Takeda Jazz pharmaceuticals Guidepoint Lighthouse and Deerfield
Funding Statement
This work was financially supported by the Michael J Fox Foundation and the Canadian Consortium on Neurodegeneration in Aging CCNA GAR holds a Canada Research Chair in Genetics of the Nervous System and the Wilder Penfield Chair in Neurosciences EAF is supported by a Foundation Grant from the Canadian Institutes of Health Research FDN grant: 154301 ZGO is supported by the Fonds de recherche du Quebec: Sante FRQS Chercheurs boursiers award and is a William Dawson Scholar
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent and ethics approval was obtained from the appropriate institutional review boards at participating institutions as described in the original studies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Four authors were removed that were mistakenly added to the authorship list.
Data Availability
The data that support the findings of this study are available from dbGaP. Parkinson's patients and controls (phs000918.v1.p1). DLB patients and controls are available from dbGaP (phs001963.v1.p1). iRBD patients and controls are available upon reasonable request from the corresponding author. Additional controls were also obtained from dbGaP; NGRC (phs000196.v2.p1) and NIND (phs000089). Code used for analysis can be found on GitHub (https://github.com/gan-orlab/APOE_SNCA)
